XTAESEMG
Market cap28mUSD
Dec 24, Last price
310.80ILS
1D
0.06%
1Q
58.65%
Name
Seach Medical Group Ltd
Chart & Performance
P/E
—
P/S
70.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.18%
Rev. gr., 5y
51.96%
Revenues
150m
+12.01%
Net income
-11m
L+208.15%
CFO
225k
-98.71%
Profile
Seach Medical Group Ltd manufactures and sells medicinal cannabis products worldwide. The company offers medicinal cannabis inflorescence and oil compounds under the Nitzan brand name. It also provides power powder and moodpicks. Seach Medical Group Ltd was founded in 2002 and is based in Ramat Gan, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 150,324 12.01% | 134,210 99.30% | 67,340 82.98% | ||||||
Cost of revenue | 152,921 | 130,099 | 62,810 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,597) | 4,111 | 4,530 | ||||||
NOPBT Margin | 3.06% | 6.73% | |||||||
Operating Taxes | 1,592 | 1,203 | 1,006 | ||||||
Tax Rate | 29.26% | 22.21% | |||||||
NOPAT | (4,189) | 2,908 | 3,524 | ||||||
Net income | (10,511) 208.15% | (3,411) -163.77% | 5,349 -55.30% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (8,110) | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 8,114 | 5,821 | 10,800 | ||||||
Long-term debt | 31,991 | 42,781 | 6,781 | ||||||
Deferred revenue | 20,387 | (2,195) | |||||||
Other long-term liabilities | 1,311 | (19,003) | 3,460 | ||||||
Net debt | 26,482 | 21,722 | (15,857) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 225 | 17,394 | (8,128) | ||||||
CAPEX | (891) | (1,235) | (1,895) | ||||||
Cash from investing activities | (5,718) | (10,217) | (3,568) | ||||||
Cash from financing activities | (6,320) | (6,933) | 7,558 | ||||||
FCF | (4,750) | (7,422) | (13,472) | ||||||
| Balance | |||||||||
Cash | 10,374 | 21,804 | 22,180 | ||||||
Long term investments | 3,249 | 5,076 | 11,258 | ||||||
Excess cash | 6,107 | 20,170 | 30,071 | ||||||
Stockholders' equity | 85,760 | 98,385 | 95,576 | ||||||
Invested Capital | 107,177 | 109,604 | 80,732 | ||||||
ROIC | 3.06% | 5.70% | |||||||
ROCE | 3.14% | 4.01% | |||||||
| EV | |||||||||
Common stock shares outstanding | 34,024 | 34,024 | 33,759 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 3,922 | 10,840 | 8,132 | ||||||
EV/EBITDA | |||||||||
Interest | 1,533 | 409 | |||||||
Interest/NOPBT | 37.29% | 9.03% | |||||||